IMNM Earnings & Financial Statements
Immunome, Inc.
$17.47
+$0.27(+1.57%)
40
Overall
50
Value
18
Tech
52
Quality
Market Cap
$2.03B
Volume
129.43K
52W Range
$13.53 - $30.06
Target Price
$35.20
IMNM earnings and financial statements: Immunome, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IMNM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14.02M | - | - |
| Operating income | -$224.11M | -$305.80M | -$109.53M | -$36.90M | -$25.20M |
| EBITDA | -$221.12M | -$303.67M | -$108.76M | -$36.29M | -$24.45M |
| Net income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | -$24.71M |
| EPS (diluted) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $683.19M | $240.24M | $148.54M | $24.05M | $57.92M |
| Total liabilities | $48.84M | $59.08M | $28.66M | $7.39M | $9.74M |
| Shareholders’ equity | $634.34M | $181.16M | $119.88M | $16.65M | $48.19M |
| Cash and equivalents | $653.50M | $143.35M | $98.68M | $20.32M | $49.23M |
| Long-term debt | $3.85M | $4.77M | $1.34M | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -$18.23M |
| Capital expenditure | -$9.69M | -$7.17M | -$831.0K | -$248.0K | -$79.0K |
| Free cash flow | -$200.60M | -$117.97M | -$8.40M | -$28.94M | -$18.30M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMNM | $17.47 | +1.6% | 129.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |